

Molecular Pharmacology Branch References

NCI60 Cell Line and Organoid Screening Laboratory

1. Kunkel MW, Coussens NP, Morris J, Taylor RC, Dexheimer TS, Jones EM, Doroshow JH, Teicher BA. HTS384 NCI60: The Next Phase of the NCI60 Screen. *Cancer Res.* 2024; 84: 2403-16.
2. Joel Morris, Mark W Kunkel, Stephen L White, Donn G Wishka, Omar D Lopez, Lori Bowles, Penny Sellers Brady, Patricia Ramsey, Julie Grams, Tiffany Rohrer, Karen Martin, Thomas S Dexheimer, Nathan P Coussens, David Evans, Prabhakar Risbood, Dmitriy Sonkin, John D Williams, Eric C Polley, Jerry M Collins, James H Doroshow, Beverly A Teicher Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems-based Resource *Mol Cancer Ther.* 2023 Aug 7;22(11):1270-1279.
3. Monks A, Zhao Y, Hose C, Hamed H, Krushkal J, Fang J, Sonkin D, Palmisano A, Polley EC, Fogli LK, Konaté MM, Miller SB, Simpson MA, Voth AR, Li MC, Harris E, Wu X, Connelly JW, Rapisarda A, Teicher BA, Simon R, Doroshow JH. The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel. *Cancer Res* 2018; 78: 6807-17.
4. El Touny LH, Hose C, Connelly J, Harris E, Monks A, Dull AB, Wilsker DF, Hollingshead MG, Gottholm-Ahalt M, Alcoser SY, Mullendore ME, Parchment RE, Doroshow JH, Teicher BA, Rapisarda A. ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow/MMRproficient cancer cells to temozolomide. *Oncotarget* 2021; 12: 2114-30.

Target Validation and Screening Laboratory

1. Sonkin D, Thomas A, Teicher BA. Cancer treatments: Past, present, and future. *Cancer Genet.* 2024; 286-287:18-24.
2. Dexheimer TS, Coussens NP, Silvers T, Jones EM, Chen L, Fang J, Morris J, Moscow JA, Doroshow JH, Teicher BA. Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor. *SLAS Discov* 2024; 29: 100186.
3. Dexheimer TS, Coussens NP, Silvers T, Wright J, Morris J, Doroshow JH, Teicher BA. Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs. *Cancer Res Commun.* 2023; 3:1648-61.
4. Kaur G, Evans DM, Teicher BA, Coussens NP. Complex tumor spheroids, a tissue-mimicking tumor model, for drug discovery and precision medicine. *SLAS DISCOVERY: Advancing the Science of Drug Discovery* 2021; 26: 1298-1314.

5. Krushkal J, Silvers T, Reinhold WC, Sonkin D, Vural S, Connelly J, Varma S, Meltzer PS, Kunkel M, Rapisarda A, Evan, D. Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets. *Clinical Epigen* 2020; 12: 1-28.
6. Evans DM, Fang, J, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Bowles L, Connelly J, Harris E. Exposure time versus cytotoxicity for anticancer agents. *Cancer Chemotherap Pharmacol* 2017; 84: 359-71.
7. Selby M, Delosh R, Laudeman J, Ogle C, Reinhart R, Silvers T, Lawrence S, Kinders R, Parchment R, Teicher BA, Evans DM. 3D models of the NCI60 cell lines for screening oncology compounds. *SLAS DISCOVERY: Advancing Life Sciences R&D* 2017; 22: 473-83.
8. Teicher BA, Silvers T, Selby M, Delosh R, Laudeman J, Ogle C, Reinhart R, Parchment R, Krushkal J, Sonkin D, Rubinstein L. Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent. *Cancer Medicine* 2017; 6: 1952-64.
9. Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudem
10. an J, Ogle C, Reinhart R, Selby M, Connelly J, Harris E, Fer N, Sonkin D, Kaur G, Monks A, Malik S, Morris J, Teicher BA. Small cell lung cancer screen of oncology drugs, investigational agents, and gene and microRNA expression. *J Nat Cancer Inst* 2016; 108: djw122.
11. Teicher BA, Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Connelly J. Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression. *Molec Cancer Therap* 2015; 14: 2452-62.

Tubulin Biochemistry and Pharmacology Laboratory and Mechanism of Action Laboratory

1. Ren W, Deng Y, Ward JD, Vairin R, Bai R, Wanniarachchi H I, Hamal KB, Tankoano PE, Tamminga CS, Bueno LMA, Hamel E, Mason RP, Trawick ML, Pinney KG. Synthesis and biological evaluation of structurally diverse 6-aryl-3-aryl-indole analogues as inhibitors of tubulin polymerization. *Eur J Med Chem* 2024; 263: 115794.
2. Milunovic MNM, Ohui K, Besleaga I, Petrasheuskaya TV, Dömötör O, Enyedy ÉA, Darvasiova D, Raptá P, Barbieriková Z, Vegh D, Tóth S, Tóth J, Kucsma N, Szakács G, Popovic-Bijelic A, Zafar A, Reynisson J, Shutalev AD, Bai R, Hamel E, Arion V B. Copper(II) complexes with isomeric morpholine-substituted 2-formylpyridine thiosemicarbazone hybrids as potential anticancer drugs inhibiting both ribonucleotide reductase and tubulin polymerization: the morpholine position matters. *J Med Chem* 2024; 67: 9069-90.
3. Arion V, Besleaga I, Raptova R, Stoica AC, Milunovic M, Zalibera M, Bai R, Igaz N, Reynisson J, Kiricsi M, Enyedy E, Raptá P, Hamel E. Are the metal identity and stoichiometry of metal complexes important for colchicine site binding and inhibition of tubulin polymerization? *Dalton Trans* 2024; 53: 12349-69.

4. Mariotto E, Canton M, Marchioro C, Brancale A, Hamel E, Varani K, Vincenzi F, De Ventura T, Padroni C, Viola G, Romagnoli R. Benzofuran-based hydroxamic acids as antimicrotubule agents. *Int J Mol Sci* 2024; 25: 7519 (35 pps).
5. Kong Y, Edler MC, Hamel E, Britton-Jenkins AR, Gillan O, Mooberry SL, Mu D, Brown ML. Synthesis and structure-activity relationship of boronic acid bioisosteres of combretastatin A-4 as anticancer agents. *Bioorg Med Chem* 2024; 116: 117999 (10 pps).
6. Ford JW, VanNatta JM, Mondal D, Lin CM, Den Y, Bai R, Hamel E, Trawick ML, Pinney KG. Drug-linker constructs bearing unique dual-mechanism tubulin binding payloads tethered through cleavable and non-cleavable linkers. *Tetrahedron* 2025; 171:134350 (17 pps).
7. Vairin R, Tamminga C, Shi Z, Borchardt C, Jambulapati J, Bai R, Wanniarachchi H, Bueno L, Hamel E, Mason RP, Trawick ML, Pinney KG. Design, Synthesis and biological evaluation of 2-phenyl indole analogues of OXi8006 as colchicine site inhibitors of tubulin polymerization and vascular disrupting agents. *Bioorg Med Chem* 2025; 118: 117981 (17 pps).
8. Spanò V, Barreca M, Rocca R, Bortolozzi R, Bai R, Carbone A, Raimondi MV, Piccionello AP, Montalbano A, Alcaro S, Hamel E, Viola G, Barraja P. Insight on [1,3]thiazolo[4,5-e]isoindoles as tubulin polymerization inhibitors. *Eur J Med Chem* 2021; 212: 113122.
9. Choudhary S, Doshi A, Lockett-Chastain L, Ihnat M, Hamel E, Mooberry SL, Gangjee A. Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer. *Bioorg Med Chem* 2021; 35: 116061.
10. Peerzada MN, Hamel E, Bai R, Supuran CT, Azam A. Deciphering the key heterocyclic scaffolds in targeting microtubules, kinases and carbonic anhydrases for cancer drug development. *Pharmacol Ther* 2021; 225: 107860.